BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects
|ClinicalTrials.gov Identifier: NCT00388492|
Recruitment Status : Unknown
Verified October 2006 by Bellos, Nicholaos C., M.D..
Recruitment status was: Not yet recruiting
First Posted : October 16, 2006
Last Update Posted : January 11, 2007
The goal of this study is to evaluate the proportion of subjects both antiretroviral experienced and virologically suppressed on lopinavir/ritonavir (LPV/r)400/100mg twice daily who maintain viral suppression after switching to lopinavir/ritonavir (LPV/r)800/200mg once daily.
The hypothesis for this study is that the majority of subjects will remain virologically suppressed with once daily dosing versus twice daily dosing and therefore quality of life will be improved with the once daily dosing of lopinavir/ritonavir (LPV/r)800/200mg.
|Condition or disease|
|Study Type :||Observational|
|Enrollment :||45 participants|
|Observational Model:||Defined Population|
|Official Title:||BLADE: "A Comparison of Once Daily LPV/r to LPV/r BID in HIV-Infected Virologically Controlled Antiretroviral Experienced Subjects"|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00388492
|Contact: Keri Neuling||214-828-4702 ext firstname.lastname@example.org|
|Contact: Denise Ramos||214-828-4702 ext email@example.com|
|United States, Texas|
|Nicholaos C. Bellos, MD||Not yet recruiting|
|Dallas, Texas, United States, 75204|
|Contact: Keri Neuling 214-828-4702 ext 122 firstname.lastname@example.org|
|Contact: Denise Ramos 214-828-4702 ext 102 email@example.com|
|Principal Investigator: Nicholaos C. Bellos, MD|
|Principal Investigator:||Nicholaos C. Bellos, MD||Nicholaos C. Bellos, MD|